Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Retooling Generic Business - 1: Daiichi Sankyo Espha Shifting Its Focus to AGs
January 29, 2016
- Shionogi Files Japan NDA for ADHD Drug Licensed from Shire
January 28, 2016
- Mochida Seeks Adenomyosis Indication for Dinagest
January 28, 2016
- 140 Hep C Patients Receive Viekirax in 1st Month
January 27, 2016
- Mochida Set to Achieve 10 Billion Yen Generic Sales in FY2015
January 27, 2016
- MSD Joins with Venture Capital to Offer BD Support for Health-Tech Startups
January 27, 2016
- Mundipharma to Merge Spectrum Unit in March, Become MAH for Zevalin
January 26, 2016
- Kyowa Kirin to Market Sandoz’s Rituximab Biosimilar in Japan
January 26, 2016
- Dispensing Pharmacies Worried about Reversal of Delivery and NHI Prices Following Re-Pricing of Gilead’s “Huge Seller” Hep C Drugs
January 21, 2016
- Maruho, Galderma Team Up to Develop, Market Skin Treatments in Japan
January 19, 2016
- Toa Eiyo to Take Over Astellas’s Marketing Authorization for Cibenol
January 19, 2016
- GSK to Resume Shipment of Hep B Drug Tenozet
January 18, 2016
- Novartis Partners with Meiji Seika Pharma to Promote COPD Drugs
January 18, 2016
- Ethical Drug Sales Jump 15.2% in November: Crecon Report
January 18, 2016
- MSD Renews Call for Reinstating Govt’s HPV Vaccine Promotion after WHO Statement
January 15, 2016
- Ono Files Etelcalcetide for Secondary Hyperparathyroidism in Japan
January 15, 2016
- Ribomic Inks New Agreement with Otsuka on Midkine Aptamer; Otsuka to Decide on In-Licensing by Year-End
January 15, 2016
- INDEE Medical Obtains Exclusive Distribution Rights in Japan for Autologous Epidermis Transplant Kit from Australian Company
January 15, 2016
- Weber Says Takeda Made “Big Decision” to Pull Plug on Metabolic R&D
January 14, 2016
- Iwaki Top Brass to Return Remunerations over Embezzlement Issue
January 14, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…